Back to Search Start Over

Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial

Authors :
Strober, B
Asahina, A
Mrowietz, U
Lebwohl, M
Foley, P
Langley, R
Barker, J
Cioffi, C
Cross, N
Wang, M
Paul, C
Strober, B
Asahina, A
Mrowietz, U
Lebwohl, M
Foley, P
Langley, R
Barker, J
Cioffi, C
Cross, N
Wang, M
Paul, C
Publication Year :
2021

Abstract

N/A

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1340014660
Document Type :
Electronic Resource

Tools

Authors Abstract Subjects Details